MUSK and myasthenia gravis: Building on this platform, Oh et al. extended CAAR-T therapy to MuSK myasthenia gravis, designing MuSK-CAAR-T cells that selectively eliminated MuSK autoantibody-producing B cells in preclinical models [165].